Relapsed or Refractory Classical Hodgkin Lymphoma research hub

A Phase 2 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

This study is testing a new combination medicine (MK-4280A) against standard chemotherapy for people with Hodgkin Lymphoma that has come back or not responded to previous treatments. We want to see if the new medicine can stop the cancer from growing for longer.